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Abstract
The diagnosis of cholangiocarcinoma (CCA) is often challenging, leading to poor prognosis. CCA arises via chronic
inflammation which may be associated with autoantibodies production. This study aims to identify IgG antibodies directed
at self-proteins and tumor-associated antigens. Proteins derived from immortalized cholangiocyte cell line (MMNK1) and
CCA cell lines (M055, M214 and M139) were separated using 2-dimensional electrophoresis and incubated with pooled
plasma of patients with CCA and non-neoplastic controls by immunoblotting. Twenty five immunoreactive spots against all
cell lines-derived proteins were observed on stained gels and studied by LC-MS/MS. Among these, heat shock protein 70
(HSP70), enolase 1 (ENO1) and ribonuclease/angiogenin inhibitor 1 (RNH1) obtained the highest matching scores and were
thus selected for further validation. Western blot revealed immunoreactivity against HSP70 and RNH1 in the majority of CCA
cases and weakly in healthy individuals. Further, ELISA showed that plasma HSP70 autoantibody level in CCA was
significantly capable to discriminate CCA from healthy individuals with an area under the receiver operating characteristic
curve of 0.9158 (cut-off 0.2630, 93.55% sensitivity and 73.91% specificity). Plasma levels of IgG autoantibodies against HSP70
were correlated with progression from healthy individuals to cholangitis to CCA (r = 0.679, P,0.001). In addition, circulating
ENO1 and RNH1 autoantibodies levels were also significantly higher in cholangitis and CCA compared to healthy controls
(P,0.05). Moreover, the combinations of HSP70, ENO1 or RNH1 autoantibodies positivity rates improved specificity to over
78%. In conclusion, plasma IgG autoantibodies against HSP70, ENO1 and RNH1 may represent new diagnostic markers for
CCA.
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Introduction
Cholangiocarcinoma (CCA) is an adenocarcinoma originating
from bile duct epithelial cells with highest incidence rates in
Northeastern Thailand [1]. In this area, CCA is associated with
the liver fluke, Opisthorchis viverrini infection through chronic
inflammation of the bile ducts [2,3] via reactive oxygen and
nitrogen species [4,5] and reactivity against the infection [6,7].
Ultrasonography currently represents the most sensitive tool for
hepatobiliary cancer detection but this is often difficult to
discriminate from cholangitis [8] and, as a result, diagnosis is
frequently delayed with dramatic effects on the outcome [9,10].
Serum carcinoembryonic antigen (CEA) and carbohydrate antigen
19-9 (CA 19-9) are commonly used when CCA is suspected but
their sensitivity and specificity are widely variable [11–13] and, as
a result, there is an urgent need for new noninvasive biomarkers.
Autoantibodies against self- or tumor-associated antigens
(TAAs) represent promising cancer biomarkers [14–18]. In several
cases, autoantibodies correlate with disease stage [19–21] and
persist longer and at higher levels than the targeted protein [22].
Mechanisms underlying the production of autoantibodies against
the bile ducts remain enigmatic [23], possibly relying on the link
with chronic inflammation [24] with oxidative stress causing the
appearance of neoepitopes [25]. Moreover, it is now largely
established that immune response to TAAs may be affected by
many mechanisms including mutated [26], misfolded [27],
overexpressed [28], aberrantly degraded [29], glycosylated [30]
and ectopically expressed [31] tumor proteins.
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Based on these observations, we sought for plasma autoanti-
bodies in patients with fluke-associated CCA and identified
immunoreactivity against heat shock protein 70 (HSP70), enolase
1 (ENO1) and ribonuclease/angiogenin inhibitor 1 (RNH1)
proteins as potential biomarkers for CCA.
Methods
Subjects
Plasma samples were obtained from 66 subjects and divided into
3 groups including healthy controls (n = 23, 17 healthy subjects
and 6 abnormal blood vessels subjects without hepatobiliary tract
abnormality, mean age 53.468 years), patients with cholangitis
(bacterial cholangitis and cholelithiasis, n = 12, mean age 58.7610
years) and CCA (of tubular and papillary types, n = 31, mean age
5669 years). Ten ml of peripheral blood were obtained by sterile
venipuncture and collected in tubes containing EDTA. Blood was
centrifuged at 3,000 g for 15 min at 4uC. Plasma samples were
stored at –80uC until analyzed. The study protocol was approved
by the Human Research Ethics Committee, Khon Kaen
University, Thailand (HE561290) and a written informed consent
was obtained from all subjects (HE521209). Patients with liver
cancer were undergoing hepatectomy at Srinagarind Hospital,
Faculty of Medicine, Khon Kaen University, Thailand. Diagnosis
of cholangitis and CCA was based on clinical, radiological,
laboratory criteria and confirmed by liver biopsy. Healthy
individuals were age- and sex-matched to patients with liver
cancer and manifested no O. viverrini eggs in stool, normal
Figure 1. Two-dimensional (2D) gel electrophoresis and western blotting. MMNK1 and CCA cell lines (M055, M214 and M139) lysates were
separated by 2D electrophoresis and stained with coomassie brilliant blue (panels A, C, E and G). Parallel gels were transferred to PVDF and incubated
with pooled plasma of patients with CCA (n = 10) and incubated with secondary anti-human IgG (panels B, D, F and H). Matching IgG autoantibodies
spots were numbered 1–14 in both CBB gels and western blot membranes. Duplicate experiments were performed. Spot numbers 1, 11 and 13 are
RNH1, ENO1 and HSP70, respectively.
doi:10.1371/journal.pone.0103259.g001
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urinalysis and normal hepatobiliary tract assessed at ultrasonog-
raphy.
Cell lines and cell culture
An immortal cholangiocyte (MMNK1) was established as
previously described [32]. Human CCA (moderately differentiate
type (M055 and M214) and squamous cell carcinoma type (M139)
were developed from Thai patients and written informed consents
were obtained from all subjects. CCA cell lines were established
and characterized as described previously [33]. CCA cell lines
were kindly provided by Prof. Banchop Sripa, Department of
Pathology, Faculty of Medicine, Khon Kaen University, Thailand.
All cell lines were cultured in HAM’s F-12 medium supplemented
with 10% heat-inactivated fetal bovine serum (FBS), 2 mmol/L
glutamine, 15 mmol/L HEPES and 14 mmol/L sodium bicar-
bonate, 100 U/ml penicillin G and 100 U/ml streptomycin. Cells
were maintained at 37uC under a 5% humidified CO2 incubator.
Cell culture materials (medium, FBS and antibiotics) were
purchased from Gibco Invitrogen (Auckland, New Zealand).
Two-dimensional (2D) gel electrophoresis and western
blotting
Pellets from MMNK1 and CCA cell lines (M055, M214 and
M139) were lysed by freeze-thaw and added with 150 ml of sample
preparation solution (8 M urea, 2 M thiourea, 4% (wt/vol)
CHAPS (3-[(3-cholamidopropyl)-dimethylammonio]-1-propane-
sulfonate), 2% (vol/vol) immobilized pH gradient (IPG) buffer
(pH 3 to 10), 40 mM dithiothreitol (DTT) and protease inhibitors
cocktail) (GE Healthcare, Piscataway, NJ, USA). Samples were
then vortexed, incubated at 4uC for 1 h and centrifuged at
12,000 rpm for 30 min at 4uC. Supernatant were collected and
protein concentration was measured using Bradford assay (Bio-
Rad Laboratories, Hercules, CA, USA) according to the
manufacturer’s protocol. Proteins (150 ug) from each cell lines
were mixed in the sample loading buffer with 0.5% IPG buffer, pI
3–10 (GE Healthcare, Tokyo, Japan) and isoelectric focusing using
the Immobiline DryStrip, pH 3–10, 7 cm (GE Healthcare) using
Ettan IPGphor II (GE Healthcare) followed by 12% SDS-PAGE.
Proteins in the gel were transferred to a polyvinylidene difluoride
membrane (PVDF membrane, Amersham Bioscience, Piscataway,
NJ, USA) and blocked with 5% skim milk, 0.1% Tween 20 in
phosphate buffer saline (PBS) for 1 h at room temperature, then
incubated with the 1:2000 diluted pooled plasma CCA samples
(n = 10) in 5% skim milk, 0.1% Tween 20 in 16PBS (PBST) for
1 h at room temperature. After washing, the membrane was
incubated with anti-human IgG HRP conjugate dilution 1:15,000
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at
room temperature. The membrane was developed using ECL
solution (GE Healthcare). The parallel 2D gels and PVDF
membranes were also stained with coomassie brilliant blue
(CBB) in order to match spots with protein in CBB gels.
Tryptic digestion and protein identification by mass
spectrometry
Following comparisons with western blot membranes, corre-
sponding spots on CBB staining gels were matched and excised.
Excised spots were prepared using tryptic digestion for LC-MS/
MS. In brief, the gel spot containing the protein was destained,
reduced and alkylated, then digested with 10 ng/ml trypsin in 50%
acetonitrile (ACN)/10 mM ammonium bicarbonate (Promega,
Madison, WI, USA) followed by incubation at room temperature
for 20 min. To keep the gels immersed throughout digestion,
20 ml of 30% ACN was added and incubated at 37uC overnight.
To extract peptide digestion products, 30 ml of 50% ACN in 0.1%
formic acid was added into the gels and incubated at room
temperature for 10 min in a shaker. Peptides extracted were
collected, dried by vacuum centrifuge and kept at 280uC for
further mass spectrometric analysis. Nanoscale LC separation of
tryptic peptides was performed with a NanoAcquity system
(Waters Corp., Milford, MA, USA) equipped with a Symmetry
C18 (5 mm, 180-mm620-mm) Trap column and a BEH130 C18
(1.7 mm, 100-mm6100-mm) analytical reversed phase column
(Waters). Samples were initially transferred with an aqueous 0.1%
formic acid solution to the trap column with a flow rate of 15 ml/
Figure 2. Western blotting analysis of HSP70 and RNH1 autoantibodies. Panel A) Recombinant human HSP70 was incubated with plasma of
healthy individuals (lane 1–5) and patients with CCA (lanes 6–12). Immunoreactive bands were detected in 5/7 patients and none of the healthy
controls. Panel B) Recombinant human RNH1 was incubated with plasma of healthy individuals (lane 1–5) and patients with CCA (lanes 6–12).
Immunoreactive bands were detected in 6/7 patients and was weak in controls. Recombinant HSP70 and RNH1 proteins were probed with pooled
healthy plasma served as negative controls (2) and pooled plasma from patients with CCA served as positive controls (+). HSP70 and RNH1 proteins
were also demonstrated by staining with coomassie brilliant blue (CBB). PH = healthy individuals, CCA = cholangiocarcinoma.
doi:10.1371/journal.pone.0103259.g002
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min for 1 min. Mobile phase A was 0.1% formic acid in water and
mobile phase B was 0.1% formic acid in acetonitrile. The peptides
were separated with a gradient of 15–50% mobile phase B over
15 min at a flow rate of 600 nl/min followed by a 3-min rinse with
80% of mobile phase B. The column temperature was maintained
at 35uC. The lock mass was delivered from the auxiliary pump of
the NanoAcquity pump with a constant flow rate of 500 nl/min at
a concentration of 200 fmol/ml of [Glu1]fibrinopeptide B to the
reference sprayer of the NanoLockSpray source of the mass
spectrometer. All samples were analyzed in one sitting. Analysis of
tryptic peptides was performed using a SYNAPT-HDMS mass
spectrometer (Waters). For all measurements, the mass spectrom-
eter was operated in the V-mode of analysis with a resolution of at
least 10,000 full-width half-maximum. All analyses were per-
formed using positive nanoelectrospray ion mode. The time-of-
flight analyzer of the mass spectrometer was externally calibrated
with [Glu1]fibrinopeptide B from m/z 50 to 1600 with acquisition
lock mass corrected using the monoisotopic mass of the doubly
charged precursor of [Glu1]fibrinopeptide B. The reference
sprayer was sampled with a frequency of 20 sec. Accurate mass
LC-MS data were acquired with data direct acquisition mode.
The energy of trap was set at collision energy of 6 V. In transfer
collision energy control, low energy was set at 4 V. The
quadrupole mass analyzer was adjusted such that ions from m/z
300 to 1800 were efficiently transmitted. The MS/MS survey was
over range 50 to 1990 Da and scan time was 0.5 sec. The spectral
data were generated in a micromass file (PKL) support for MS/
MS Ion Search using the MASCOT engine program (Matrix
Science, London, UK). MS data were searched against the NCBI
database for human proteins and the search was carried out with
the following parameters: MS/MS Ion Search using trypsin
enzyme, carbamidomethylated cysteine as fixed modifications;
oxidation of methionine residues as a variable modification used,
monoisotopic mass values and unrestricted protein mass. Peptide
mass tolerance was 61.2 Da, fragment mass tolerance was
60.6 Da and maximum of zero to one missed cleavage. ESI-
QUAD-TOF was the instrument type. All identified proteins
exhibited a Mascot score greater than 66 were considered
statistically significant (P,0.05).
Plasma autoantibodies by western blotting
To validate autoantibodies against HSP70, ENO1 and RNH1
as CCA markers, 0.2 mg of recombinant human full-length HSP70
(Sigma-Aldrich, St. Louis, MO, USA), ENO1 and RNH1
(Abnova, Walnut, CA, USA) proteins were separated on 10%
SDS-PAGE gel and transferred to a PVDF membrane (Amersham
Bioscience, Piscataway, NJ, USA) membrane (Amersham Biosci-
ence, Piscataway, NJ, USA) for 1 h at 0.35A. The membranes
were cut and incubated with individual plasma samples (dilution
1:250) of representative cases from healthy controls (n = 5) or
patients with CCA (n= 7). Then, the membranes were incubated
with anti-human IgG HRP conjugated, dilution 1:2,500 (Santa
Cruz Biotechnology) diluted in 2% skim milk/PBST for 1 h at
room temperature. The membranes were developed using ECL
solution (GE Healthcare). Pooled healthy plasma (negative control)
and pooled plasma from patients with CCA (positive control) were
performed in the same run.
Plasma autoantibodies by enzyme-linked
immunosorbent assay
Plasma anti-HSP70, ENO1 and RNH1 IgG autoantibodies
were measured by indirect ELISA in 66 plasma samples from
healthy individuals (n = 23), patients with cholangitis (n = 12) and
CCA (n= 31). The 96-well MaxiSorp immunoplates (Nunc,
Roskilde, Denmark) were coated with 100 ml of recombinant
human full-length HSP70, ENO1 or RNH1 (each, 1 mg/ml in 16
PBS) at 4uC overnight and washed once with 16 PBST. The
plates were blocked with 100 ml of 5% skim milk for 2 h at room
temperature and washed two times with 16 PBST. Then, the
reactions were added with 100 ml of each 250-fold diluted plasma
samples in dilution buffer (16PBS pH 7.4, 5% skim milk, 0.05%
Tween 20) and incubated for 1 h at 37uC. After washing three
times with 16 PBST, 100 ml of 1:4,000 goat anti-human IgG-
HRP conjugated antibody was added and incubated for 1 h at
room temperature. The plates were then washed five times with
16 PBST. Finally, 100 ml of 3,39,5,59-tetramethylbenzidine
substrate (Thermo Scientific, West Palm Beach, FL, USA) was
added and the reaction was stopped with 3M H2SO4. The
absorbance was read at 450 nm using ELISA reader (Tecan AG,
Switzerland) and PBS was used as blank control.
Statistical analysis
Statistical analyses were performed using SPSS version 17.0
(IBM, Armonk, NY, USA). Plasma levels of autoantibodies against
HSP70, ENO1 and RNH1 proteins between patients groups were
determined using student’s t test or non-parametric Mann-
Whitney test. The correlation of HSP70 autoantibody level and
disease progression across three groups, i.e. healthy controls,
cholangitis and CCA, was analyzed by Spearman’s rank correla-
tion. The chi-square test was used to analyze the correlation
between autoantibodies and the clinicopathological parameters.
Diagnostic accuracy was assessed using the receiver operating
characteristic (ROC) curve which was constructed by plotting the
sensitivity versus (100%-specificity) and area under the curve
(AUC) with 95% confidence intervals was calculated for each
marker. P values lower than 0.05 were considered statistically
significant.
Results
Identification of novel plasma autoantibodies
Eleven immunoreactive spots (spots No. 1–11) were successfully
matched with MMNK1 cell line-derived proteins (Figure 1A–1B).
In addition, three (spots No. 9–11), four (spots No. 8–11) and
seven (spots No. 8–14) immunoreactive spots were successfully
matched with M055, M214 and M139 CCA cell lines-derived
proteins, respectively (Figure 1C–1H). Among all matched immu-
noreactive protein spots, three were found to be shared in all cell
lines (spots number 9–11) and one of them was identified as
enolase 1. Identification of autoantibodies against MMNK1
(Table 1), M055 (Table 2), M214 (Table 3) and M139 (Table 4)
Figure 3. Plasma levels of HSP70, ENO1 and RNH1 autoantibodies by ELISA. Plasma levels of autoantibodies against HSP70, ENO1 and
RNH1 were determined in clinical groups including cholangitis (n = 12), CCA (n = 31) and healthy controls (n = 23). Panel A) HSP70 autoantibody level
is significantly higher in CCA compared to cholangitis and healthy controls. Panel B) Receiver operating characteristic (ROC) curves of HSP70
autoantibody in patients with CCA vs healthy controls. Panel C) ENO1 and Panel E) RNH1 autoantibodies are significantly higher in CCA than healthy
controls. Panels D and F) ROC curves of ENO1 and RNH1 autoantibodies in patients with CCA vs healthy controls. Data are illustrated as mean 6 SD
using student’s t test or non-parametric Mann-Whitney test; *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0103259.g003
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cell lines-derived proteins including their GI number, biological
process and protein score was performed. Immunoreactivity
against ribonuclease/angiogenin inhibitor 1 (RNH1, spot No. 1
in MMNK1 cell line), enolase 1 (ENO1, spot No. 11 in all cell
lines) and heat shock protein 70 (HSP70, spot No. 13 in M139 cell
line), which showed statistically significant of matched proteins
with the highest protein score from each cell lines, was observed.
Plasma HSP70, ENO1 and RNH1 autoantibodies
Recombinant HSP70, ENO1 and RNH1 proteins were used as
antigens and then probed with the plasma of CCA and healthy
individuals using western blot. The 70 kDa immunoreactive band
corresponding to HSP70 was reactive with 5/7 CCA but none of
the healthy individual (Figure 2A) plasma samples. RNH1
autoantibody was detected in 6/7 CCA plasma and was weak in
controls as a 76 kDa immunoreactive band (Figure 2B). None of
the studied plasma manifested ENO1 autoantibody at western blot
(data not shown) but confirmed its reactivity at ELISA (see below).
Using ELISA to test reactivities against all three antigens, the
mean OD of blank, negative and positive controls were
0.04560.02, 0.21760.01 and 0.51060.04 for anti-HSP70, were
0.05660.02, 0.54960.06 and 1.14060.1 for anti-RNH1 and were
0.05360.01, 0.52560.06 and 1.06360.11 for anti-ENO1,
respectively. The highest titers of HSP70 autoantibody were
found in CCA compared to cholangitis (P,0.05) and healthy
individuals group (P,0.001, Figure 3A). Interestingly, when
correlation of HSP70 autoantibody level and disease was analyzed
across healthy controls, cholangitis and CCA group using
Spearman’s rank correlation, HSP70 autoantibody levels mani-
fested a significant trend (r = 0.679, P,0.001). ENO1 autoanti-
body was undetectable by western blotting but was successfully
demonstrated by ELISA. Plasma levels of ENO1 (Figure 3C) and
RNH1 (Figure 3E) autoantibodies in cholangitis were significantly
higher compared to healthy individuals (P,0.01). A statistically
significant increase of ENO1 (P,0.001) and RNH1 (P,0.001)
autoantibodies in CCA were observed compared to healthy
individuals. Further, plasma ENO1 and RNH1 autoantibodies
were higher in CCA compared to cholangitis but failed to reach
statistical significance.
Sensitivity and specificity of HSP70, ENO1 and RNH1
autoantibodies
The sensitivity and specificity of anti-HSP70, ENO1 and RNH1
autoantibodies are illustrated in Table 5. To discriminate patients
with CCA from healthy controls, an anti-HSP70 cut-off value of
0.2630 yielded a sensitivity of 93.55% and a specificity of 73.91%
(Table 5) with AUC of 0.9158 (Figure 3B). The positive predictive
value was 82.86% and the negative predictive value was 89.47%.
In the case of ENO1 autoantibody, the cut-off value of 0.7185
allowed a sensitivity of 80.65% and specificity of 78.26% (Table 5)
with AUC of 0.8576 (Figure 3D) with a positive predictive value of
83.33% and a negative predictive value of 75.00%. For the RNH1
autoantibody, a cut-off value at 0.5615 had a sensitivity of 93.55%
and a specificity of 78.26% (Table 5) with AUC of 0.8380
(Figure 3F). The positive predictive and negative predictive values
were 85.29% and 90.00%, respectively.
Anti-HSP70, ENO1 and RNH1 autoantibodies levels could be
distinguished between healthy controls and cholangitis (P,0.01,
AUC=0.8170, 0.8043 and 0.7790, respectively). The sensitivity
and specificity rates of anti-HSP70 were 75% and 73.91%, of anti-
ENO1 75% and 78.26% and of anti-RNH1 83.33% and 65.22%,
respectively (Table 5). In addition, to discriminate between
cholangitis and CCA the sensitivity and specificity of anti-
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HSP70 were 51.61% and 83.33%, respectively (P,0.05,
AUC=0.7191).
The discriminating power of the possible combinations of
different reactivities of autoantibodies (i.e. HSP70 and ENO1,
HSP70 and RNH1, ENO1 and RNH1, HSP70 and ENO1 and
RNH1) was analyzed (Table 6) and the specificity exceeded 78%
when compared to a single marker (Table 5) with only a slight
reduction in sensitivity.
Clinical correlation of HSP70, ENO1 and RNH1
autoantibodies
The correlation between HSP70, RNH1 and ENO1 autoanti-
bodies with the patient clinicopathological parameters is illustrated
in Table 7. Also in consideration of the high baseline OD values
observed with negative controls, OD levels of autoantibodies
against HSP70, RNH1 and ENO1 were arbitrarily arrayed into
high (OD.0.2630 for anti-HSP70, OD.0.7185 for anti-ENO1
and OD.0.5615 for anti-RNH1) or low (OD#0.2630 for anti-
HSP70, OD#0.7185 for anti-ENO1 and OD#0.5615 for anti-
RNH1). Remarkably, the comparison between the CCA invasive
phenotype and carcinoma in situ or mucinous type, identified
elevated HSP70 and ENO1 autoantibodies as significantly
correlated with CCA invasiveness (7 cases had high OD vs 5
cases had low OD of autoantibodies for invasive type and 6 cases
had low OD vs no cases with high OD of autoantibodies for
carcinoma in situ or mucinous type, P=0.038 by chi-square test).
Nonetheless, no correlation between autoantibodies levels and age,
sex, histopathologic features, metastasis, or survival were seen
(data not shown).
Discussion
Post-translational modification of self-proteins can lead to
aberrant protein expression or neo-antigens which may then
cause the appearance of circulating autoantibodies [28–30], as
observed in CCA [34]. We hypothesized that excess of modified
proteins may contribute to induce autoantibodies in CCA and
report for the first time that IgG autoantibodies against HSP70,
ENO1 and RNH1 are specific to CCA and may prove candidates
for challenging cases.
Among CCA-associated autoantigens identified in our study
(Table 1–4), HSP70 protein is possibly the most intriguing because
this is a stress response protein involved in various cell processes
such as folding, assembly of newly synthesized proteins and the
inhibition of apoptosis acting on the caspase-dependent pathway
[35]. Overproduction of HSP70 leads to increased resistance
against apoptosis-inducing agents such as tumor necrosis factor-a
and doxorubicin [36] and can promote tumor growth and
metastatic potential in rodent models [37]. Expression of HSP70
was found in CCA metastasis tissues [38] and could be used as
marker in CCA [39]. Moreover, autoantibodies against HSP70
have been identified in esophageal squamous cell carcinoma, lung
disease and alcohol-related disease [40–42] but not in CCA where
elevated levels of carbonylated HSP70 protein were reported [34].
Our ELISA data support the view that autoantibodies against
HSP70 may discriminate CCA from cholangitis, a risk condition
for bile duct cancer, cholangitis from healthy individuals and CCA
from healthy individuals (Table 5). Its level increased from healthy
controls to cholangitis to CCA, suggesting that HSP70 autoanti-
bodies might be used as not only for early marker but also for
screening risk marker of CCA. High sensitivity (93.55%) and
specificity (73.91%) of the test to discriminate between CCA from
healthy individuals suggest that HSP70 autoantibodies might serve
as a novel marker for CCA in addition to commonly used markers
such as CA 19-9 (sensitivity 66% and specificity of 97%) [43] and
CEA (sensitivity 68.0% and specificity of 81.5%) [44] which may,
however, manifest similar performances for cancers other than
CCA [13,45,46]. Also, IgG autoantibodies to HSP70 had higher
sensitivity (93.55%) than protein level (80%) for CCA diagnosis
[39]. In this case, HSP70 autoantibody level was significantly
higher in CCA compared to cholangitis (P,0.05). Plasma HSP70
autoantibody level was positively correlated with the diseases
progression from healthy control to cholangitis to CCA groups
(r = 0.679, P,0.001), suggesting that its level correlates with the
neoplastic potential and might be used as early marker of CCA.
Interestingly, the specificity of HSP70 autoantibody levels in CCA
was improved when combined with autoantibodies against ENO1
or RNH1 (Table 6). Therefore, using multiple autoantibodies
rather than single marker may enhance CCA detection.
We demonstrated that plasma ENO1 autoantibody levels are
also significantly increased in CCA and cholangitis compared to
healthy control. ENO1, a multifunctional protein, is a glycolytic
enzyme which is highly expressed in liver tissue and cytoplasm of
hyperplastic bile ducts and overexpressed in different cancer types
[47]. This protein is crucial to the response to hypoxia by tumor
cell by increasing cell anaerobic metabolism [48] and its post-
translational modifications by acetylation, methylation and phos-
phorylation could also be used for diagnostic and prognostic value
in oncology [47]. Moreover, ENO1 is found on the surface of
CCA cells and its overexpression is associated with poor prognosis
and tumor invasiveness [49]. Western blot failed to identify ENO1
autoantibody in our series and we speculate that this may due to
the loss of antigenicity of this protein during protein denature
process for SDS-PAGE and the positive ELISA results support this
view. Further, autoantibodies against RNH1 proteins were
identified in CCA. RNH1 regulates the localization and activity
of angiogenin which is involved in cell growth and survival
mechanisms [50] as well as in cancer establishment, growth and
metastasis [51]. RNH1 regulates the reactive oxygen species
Table 6. Diagnostic performance (sensitivity, specificity, predictive values) of the possible combination of autoantibodies against
HSP70, RNH1 and ENO1 in patients with CCA vs healthy controls.
Combination Sensitivity (%) Specificity (%) PPV (%) NPV (%)
HSP70+ENO1 77.42 82.61 85.71 73.08
HSP70+RNH1 87.10 82.61 87.10 82.61
RNH1+ENO1 74.19 78.26 82.14 69.23
HSP70+ENO1+RNH1 70.97 82.61 84.62 67.86
PPV = positive predictive value, NPV = negative predictive value.
doi:10.1371/journal.pone.0103259.t006
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contribution to drug resistance in gastric cancer [52] and the
growth and metastasis of bladder cancer [53].
CCA frequently manifests heterogeneous characteristics which
might produce the different level of autoantibodies production.
Our results demonstrate that circulating HSP70, ENO1and
RNH1 autoantibodies levels are highest in CCA with a wide
variability. Absorbance values in CCA group are high in some
cases in parallel with elevated OD values in negative controls. In
addition, although autoantibodies against HSP70, ENO1 and
RNH1 proteins were not significantly associated with histopath-
ologic features, metastasis, or survival, plasma HSP70 and ENO1
autoantibodies levels were able to discriminate between carcinoma
in situ or mucinous from invasive phenotype of CCA. These
findings are in agreement with the observation of autoantibody
production in Helicobacter pylori infection-associated gastric
cancer [15].
In conclusion, our data from a proteomic approach to a well-
defined clinical cohort of patients demonstrate that CCA plasma
include several IgG autoantibodies against host proteins and TAAs
which are described herein for the first time. Higher level of
HSP70, RNH1 and ENO1 autoantibodies are observed in CCA
but lower level in healthy individuals or in patients with conditions
that pose a clinical challenge to the physician. Underlying
mechanisms remain unclear and warrant further studies. In
particular, the combination of HSP70, ENO1 and RNH1
autoantibodies reactivities represent a good candidates as a new
biomarker for CCA and should thus be investigated in a large-
scale prospective study in high-risk subjects such as liver fluke
infected Thai subjects.
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